ANNEXON, INC. Retained Earnings
ANNEXON, INC. (ANNX) had Retained Earnings of -$1.02 billion as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.02B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$961.53M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$917.39M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$869.13M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.02B 10-Q · filed 2026-08-12 |
| 2026-03-31 | -$961.53M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$917.39M 10-Q · filed 2026-08-12 |
| 2025-09-30 | -$869.13M 10-Q · filed 2025-11-10 |
| 2025-06-30 | -$814.21M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$765.05M 10-Q · filed 2025-05-12 |
| 2024-12-31 | -$710.70M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$662.11M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$627.28M 10-Q · filed 2024-08-12 |
| 2024-03-31 | -$597.67M 10-Q · filed 2024-05-13 |
| 2023-12-31 | -$572.50M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$544.61M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$512.13M 10-Q · filed 2023-08-07 |
| 2023-03-31 | -$476.94M 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$438.26M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$403.88M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$368.82M 10-Q · filed 2022-08-08 |
| 2022-03-31 | -$331.69M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$296.31M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$258.94M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$223.35M 10-Q · filed 2021-08-16 |
| 2021-03-31 | -$192.00M 10-Q · filed 2021-05-17 |
| 2020-12-31 | -$165.99M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$142.80M 10-Q · filed 2020-11-16 |
| 2020-06-30 | -$127.16M 10-Q · filed 2020-09-08 |
| 2019-12-31 | -$102.58M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |